Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI
Status: | Active, not recruiting |
---|---|
Conditions: | Hospital, Orthopedic |
Therapuetic Areas: | Orthopedics / Podiatry, Other |
Healthy: | No |
Age Range: | 18 - 65 |
Updated: | 4/21/2016 |
Start Date: | August 2011 |
End Date: | August 2016 |
Acute and Chronic Effects of an Anticholinergic Agent or a Long-Acting Beta 2 Agonist on Levels of Exhaled Nitric Oxide and Pulmonary Function in Persons With Tetraplegia
To determine the acute and chronic effects of a short course of treatment on spinal cord
injured (SCI) individuals with either an anticholinergic agent (tiotropium) or with a β₂
agonist (Salmeterol) on:
- Fraction of expired NO (FeNO)
- Selected Biomarkers of inflammation in exhaled breath condensates (EBC)
- Pulmonary function, as measured by pulmonary function tests and body plethysmography
injured (SCI) individuals with either an anticholinergic agent (tiotropium) or with a β₂
agonist (Salmeterol) on:
- Fraction of expired NO (FeNO)
- Selected Biomarkers of inflammation in exhaled breath condensates (EBC)
- Pulmonary function, as measured by pulmonary function tests and body plethysmography
Inclusion Criteria:
1. Chronic Spinal Cord Injury (>1 year post-injury)
2. All American Spinal Injury Association (ASIA) classifications
3. Stable tetraplegia (level of injury C3-C8, non-ventilator dependent)
4. Age 18-65 years
Exclusion Criteria:
1. Smoking, active or history of smoking within last 6 months;
2. Active respiratory disease;
3. Known history of asthma during lifetime or recent (within 3 months) respiratory
infections;
4. Use of medications known to affect the respiratory system;
5. Use of medications known to alter airway caliber;
6. Coronary heart and/or artery disease;
7. Hypertension;
8. Adrenal insufficiency;
9. Pregnancy;
10. Severe Milk Protein Allergy;
11. Lack of mental capacity to give informed consent;
12. Previous allergic reaction or hypersensitivity to salmeterol or tiotropium;
13. Individuals taking medication(s) with known /potential drug interactions or suggested
therapy modification for concomitant use with salmeterol or tiotropium such as:
(1) selective alpha-/beta- blockers: carvedilol, labetalol; (2) non-selective
beta-blockers: Carteolol; Levobunolol; Metipranolol; Nadolol; Penbutolol; Pindolol;
Propranolol; Sotalol; Timolol); (3) CYP3A4 Inhibitors: (e.g, Atazanavir; Clarithromycin;
Conivaptan; Darunavir; Delavirdine; Fosamprenavir; Imatinib; Indinavir; Isoniazid;
Itraconazole; Ketoconazole; Lopinavir; Nefazodone; Nelfinavir; NiCARdipine; Posaconazole;
QuiNIDine; Ritonavir; Saquinavir; Telithromycin; Voriconazole; (4) Iobenguane I 123 /
Sympathomimetics: Albuterol; Aminophylline; Arformoterol; Armodafinil; Benzphetamine;
Caffeine; Dexmethylphenidate; Dextroamphetamine; Diethylpropion; Dipivefrin; DOBUTamine;
DOPamine; Doxapram; Dyphylline; EPHEDrine; EPINEPHrine; Fenoterol; Formoterol;
Isometheptene; Levalbuterol; Levonordefrin; Lisdexamfetamine; Metaproterenol;
Methamphetamine; Methylphenidate; Midodrine; Modafinil; Naphazoline; Norepinephrine;
Oxymetazoline; Phendimetrazine; Phentermine; Phenylephrine; Pirbuterol; Propylhexedrine;
Pseudoephedrine; Sibutramine; Terbutaline; Theophylline; Xylometazoline.
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials